Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Date:6/17/2008

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the corporate overview on Monday, June 23, 2008 at 1:05pm Eastern Time (10:05am Pacific Time) during the Leerink Swann Pain Roundtable Conference at the Sofitel Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relations

Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.

858-436-1400 858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
2. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
4. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
5. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
11. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events ... building events, new program offerings and company expansion. , This is largely ... include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand for ...
(Date:12/8/2016)... , December 8, 2016 AskLinkerReports.com has ... analysis, titled Global Amyloglucosidase Industry 2016 Market Research Report. From ... and industry chain overview are all covered in the report. ... and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
(Date:12/8/2016)... December 8, 2016 ... Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ NGS-Panels ... FH Panels, das ein schnelles und kostengünstiges Studium ... Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide ... einem einzigen kleinen Panel und ermöglicht eine individuelle ...
Breaking Biology Technology:
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):